Fintech PR

Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs

Published

6 hours ago

October 24, 2024

USA News Group News Commentary
Issued on behalf of PlantX Life Inc.

VANCOUVER, BC, Oct. 24, 2024 /PRNewswire/ — USA News Group News Commentary – With more than 100 million Americans struggling with obesity, and obesity rates increasing on every continent, it’s no wonder why analysts at SNS Insider are projecting the Weight Loss Drugs Market to grow at a whopping 43.73% CAGR through 2032. It’s one of the fastest growing markets in pharmaceuticals, with nearly one in four employers saying they’re either somewhat or very likely to begin covering the cost of anti-obesity medications within the next year. Health and wellness companies are responding in kind, with recent market developments coming from: PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF), Novo Nordisk A/S (NYSE: NVO), Eli Lilly and Company (NYSE: LLY), Viking Therapeutics, Inc. (NASDAQ: VKTX), and Roche Holding AG (OTCQX: RHHBY).

The article continued: According to Morgan Stanley, the global market for blockbuster obesity drugs could increase by more than 15x over the next five years, as their benefits expand beyond weight loss, with expected implications for consumer goods and longevity. With big pharma players entering the race, new weight loss drugs could be developed even faster.

PlantX Life Inc. Announces Joint Venture with LIV3 to Launch SugarShield Supplement Addressing the USD 5.24 Billion Weight Loss Management Supplement Market

PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF), a pioneer in building strong communities and operating innovative experiential online and in-store platforms that make it easier for individuals to lead happier and healthier lives, today announced a joint venture with LIV3, founded by Christopher Mearns, to launch their SugarShield supplement. Aimed at addressing the growing US$5.24 billion Weight Loss Management Supplement Market, PlantX will manage the design of SugarShield’s branding and packaging as part of the JV, while also developing a user-friendly e-commerce platform to support the supplement’s launch. PlantX Life will lead all marketing intitiatives, including utilizing its proprietary SEO strategies to build the brand’s presence, while Chris Mearns will oversee the product supply. Net profits from all sales will be shared equally, with a 50/50 split.

“As the weight loss supplement market continues to expand, driven by excitement around the popularity in products once designed for treating effects of type 2 diabetes, we at PlantX see this as an opportunity to offer a plant-based alternative without the synthetic properties,” said Lorne Rapkin, CEO of PlantX. “We believe Chris Mearns has developed what can be considered ‘nature’s Ozempic’ with SugarShield. We’re confident that the branding, packaging, and website we create will reflect the innovation and benefits of this product, making it stand out in the growing weight management market.”

The joint venture with PlantX will provide LIV3 with the resources to create a strong online presence for SugarShield. PlantX’s expertise in branding and digital platforms will help the supplement reach health-conscious consumers worldwide.

LIV3 suggests that SugarShield is designed to help users boost energy, curb cravings, and simplify weight management—all without the need for restrictive diets. After years of development, Christoper Mearns has created a formula that provides consumers with the health benefits typically associated with sugar-free diets, while fitting seamlessly into everyday lifestyles. According to Mearns, the supplement works by reducing uric acid, a key contributor to cellular stress, enabling users to improve their metabolic health.

“With LIV3’s SugarShield, consumers can detox from the negative effects of fructose without changing their diet,” said Christopher Mearns, founder of LIV3. “This supplement improves energy levels through enhanced mitochondrial function, supports glucose utilization, and increases insulin sensitivity, leading to weight loss and improved metabolic conditions. We’ve already begun designing the branding and packaging with the PlantX team, and we’re very excited about the upcoming launch. Simply put, our metabolic health was broken by daily fructose intake, and luteolin is the answer because it blocks the harmful effects of fructose.”

An integral part of this collaboration is Paul Gross, a long-time member of PlantX’s medical panel. Dr. Gross has played a crucial role in validating the medical science behind SugarShield, ensuring that the supplement’s formulation is both effective and grounded in scientific research. His expertise and support have been instrumental in building confidence in the potential benefits of SugarShield, allowing both PlantX and LIV3 to bring this innovative product to market with the assurance of its efficacy.

This joint venture aligns with PlantX’s ongoing commitment to expanding its plant-forward wellness offerings while tapping into the rapidly growing health and supplement sectors.

CONTINUED… Read this and more news for PlantX Life at: https://usanewsgroup.com/2024/10/08/from-plants-to-plates-wellness-delivered/

In other industry developments and happenings in the market this week include:

Novo Nordisk A/S (NYSE: NVO), the company behind Ozempic, recently announced that its oral semaglutide (Rybelsus®) (the active ingredient in Ozempic and Wegovy) reduced the risk of major adverse cardiovascular events by 14% in adults with type 2 diabetes, according to the SOUL trial. The randomized, double-blinded study enrolled 9,650 participants with type 2 diabetes and cardiovascular or chronic kidney disease, with 49% also receiving SGLT2 inhibitors during the trial.

“We are pleased to see that the results from SOUL demonstrate that oral semaglutide reduces the risk of cardiovascular events and that the benefits of oral semaglutide come on top of standard of care,” said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. “Approximately one in three adults with type 2 diabetes also have cardiovascular disease; therefore, it is crucial to have therapies that can address both conditions.”

The trial met its primary objective by showing a 14% reduction in MACE for those treated with oral semaglutide compared to placebo. The primary endpoint, defined as the first occurrence of cardiovascular death, non-fatal heart attack, or non-fatal stroke, saw contributions from all three components, confirming oral semaglutide’s superior MACE reduction.

Eli Lilly and Company (NYSE: LLY), maker of Ozempic and Wegovy competitor drugs Mounjaro and Zepbound, recently said it had sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets. The new lawsuits against Pivotal Peptides, MangoRx, and Genesis Lifestyle Medicine of Nevada are the first to target copycat tirzepatide since the U.S. Food and Drug Administration (FDA) removed the drug from its short supply list earlier this month.

“Lilly is bringing these actions to protect American consumers from direct patient safety risks,” said a Lilly spokesperson, adding that the defendants were making false claims regarding efficacy and safety, while also misleading consumers about the clinical data supporting those claims.

Earlier this year, Eli Lilly already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, which is also approved to treat type 2 diabetes under the brand name Mounjaro. Lilly is seeking court orders barring the vendors from selling their drugs claiming to contain tirzepatide and unspecified monetary damages.

Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced back in June that it had presented preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84^th Scientific Sessions of the American Diabetes Association. The presentation highlighted the effects of treatment on body weight, food intake and metabolic profile in healthy rats and diet-induced obese (DIO) mice as compared to control cohorts treated with vehicle or the dual amylin and calcitonin receptor agonist cagrilintide.

“The amylin receptor plays an important role in food intake and metabolic control, making it an attractive target for therapeutic intervention in obesity,” said Brian Lian, Ph.D., CEO of Viking. “These data demonstrate the potent activity of a series of novel, internally developed, amylin and calcitonin dual agonists and represent an exciting expansion of our pipeline in obesity and metabolic diseases. This program provides Viking with additional opportunities to develop novel, differentiated therapies for obesity with potentially best-in-class profiles.”

Roche Holding AG (OTCQX: RHHBY), a Swiss-based global pharmaceutical leader, recently told investors that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics have the combined potential of more than US$3.6 billion in annual sales. According to a presentation Roche gave, the revenue projection applies on aggregate to weekly injection CT-388—which is similar to Lilly’s Zepbound—and daily pill CT-996 as well as CT-868 against type 1 diabetes. In total, at least seven drugs in Roche’s development pipeline have peak sales potential of more than US$3.6 billion.

According to a report from Financial Times, Roche is planning to launch 20 medicines by the end of the decade, while cutting research costs for new drugs by a fifth.

“We want to make sure our engine works extremely efficiently,” said Thomas Schinecker, CEO of Roche, in the presentation that outlined a focus on oncology, haematology, neurology, cardiovascular and metabolic diseases, eye diseases and immune diseases. “The bar is high.”

Source: https://usanewsgroup.com/2024/10/08/from-plants-to-plates-wellness-delivered/

CONTACT:
USA NEWS GROUP
[email protected]
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for PlantX Life Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of PlantX Life Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of PlantX Life Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of PlantX Life Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of PlantX Life Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/health-and-wellness-industry-embraces-surge-in-demand-for-weight-loss-drugs-302286062.html

Fintech PR

Saudi Arabia’s Ministry of Industry and Mineral Resources Invites Mining Companies to Join Its 7th Licensing Round

Published

31 mins ago

October 24, 2024

CISION (PR Newswire)

RIYADH, Saudi Arabia, Oct. 24, 2024 /PRNewswire/ — The Ministry of Industry and Mineral Resources (MIM) is inviting exploration and mining companies to participate in its 7th round of exploration licensing. The licensing round, consisting of 7 sites with a total area of more than 1070 sq. km, will be open for bidding from mid Of October, with Successful bidders set to be announced in December.

The sites up for auction include;

Wadi al Lith: covers an area of 243.87 km2 and is located within the Mecca Region, 200 km from Jeddah. Commodities on the site include Cu, Au, and Zn.
Jabal Baudan: covers an area of 244.92 km2 and is approximately 200km south of Jeddah. The site contains commodities like Cu, Au, and Zn.
Jabal Sabha: covers an area of 171.5 km² in the central part of Saudi Arabia, approximately 650km from the Jeddah port. Commodities include Ag/Pb/Zn (Nb, Au, Co).
Jabal al Ad Dimah: covering an area of 210.90 km2, is located approximately 200km south of Jeddah. It contains deposits of Cu, Au, and Zn.
Jabal al Klah North: is part of the Ad Dawadimi Terrane located in the eastern part of the Arabian Shield, 750 km northeast of Jeddah and 320 km from Riyadh. It covers an area of 98,15 km2 and contains large deposits of Ag, Pb, and Zn.
Jabal al Klah South: covers an area of 19,21 km2. The site is part of Ad Dawadimi Terrane, located in the eastern part of the Arabian Shield, 750 km northeast of Jeddah and 320 km from Riyadh. Commodities include Ag, Pb, and Zn.
Umm Hijlan (Mamilah): covers an area of 78.4 km².The site is located in Mecca region, approximately 270km from the Jeddah port. Commodities include Au,Pb and Cu

Interested investors are invited to view the Information Memorandum by visiting Ta’adeen website at https://taadeen.sa/en/mining-bids to access the data room for the sites.

Saudi Arabia offers several competitive incentives to support investors across various sectors and industries. These include 75% co-funding for capital expenditure (CAPEX), a five-year exemption on royalty fees, discounts of up to 30% for local downstream processing (with potential savings of up to 90%), a competitive 20% corporate tax rate, and the advantage of 100% foreign direct ownership.

Logo: https://mma.prnewswire.com/media/2540025/Saudi_Ministry_of_Industry_and_Mineral_Resources_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/saudi-arabias-ministry-of-industry-and-mineral-resources-invites-mining-companies-to-join-its-7th-licensing-round-302286482.html

Fintech PR

Kindred Group applies for delisting

Published

2 hours ago

October 24, 2024

CISION (PR Newswire)

SLIEMA, Malta, Oct. 24, 2024 /PRNewswire/ — La Française des Jeux SA’s (“FDJ”) recommended public offer to the holders of Swedish Depository Receipts (the “SDRs”) in Kindred Group plc (“Kindred” or the “Company”) to tender all their SDRs in the Company at a price of SEK 130 in cash per SDR (the “Offer”) was declared unconditional on 3 October 2024. After the end of the extended acceptance period, FDJ controls in total approximately 98.60 percent of the outstanding SDRs in the Company. Against this background, the board of directors of Kindred has today applied for delisting of the SDRs in Kindred from Nasdaq Stockholm.

On 22 January 2024, FDJ announced a recommended public cash offer to the holders of SDRs in Kindred to tender all their SDRs in the Company at a price of SEK 130 in cash per SDR. On 3 October 2024, FDJ announced that the Offer had been accepted to such an extent, as at the end of the initial acceptance period on 2 October 2024, that FDJ would become the owner of 90.66 percent of all the outstanding SDRs in Kindred and declared the Offer unconditional. Since the time of announcement of the Offer, FDJ had also acquired an additional 2,400,000 SDRs, corresponding to approximately 1.11 percent of the outstanding SDRs in Kindred, from Veralda at a price not exceeding the price in the Offer. As a result, FDJ controlled in total 198,059,291 SDRs, corresponding to approximately 91.77 percent of the outstanding SDRs in the Company.^[1]

In order to provide the remaining holders of SDRs in the Company with the opportunity to accept the Offer, FDJ extended the acceptance period of the Offer until and including 18 October 2024. During the extended acceptance period, the Offer has been accepted by SDR holders with a total of 14,734,917 SDRs, corresponding to approximately 6.83 percent of the outstanding SDRs in the Company. After the end of the extended acceptance period, FDJ thus controls in total 212,794,208 SDRs, corresponding to approximately 98.60 percent of the outstanding SDRs in the Company. FDJ has on 23 October 2024 initiated squeeze-out proceedings of the SDRs in Kindred not held by FDJ, and requested that the board of directors of Kindred applies for delisting of the SDRs in the Company from Nasdaq Stockholm.

In light of the above, the board of directors of Kindred has today, in accordance with FDJ’s request, applied for delisting of the SDRs in the Company from Nasdaq Stockholm. Kindred will announce the last day of trading as soon as Nasdaq Stockholm has confirmed the date to the Company.

For more information:
Patrick Kortman, Interim CFO
[email protected]

The information was submitted for publication, through the agency of the contact person set out above, at 17:55 (CET) on October 24, 2024.

About Kindred Group

Kindred Group is one of the world’s leading online gambling operators with business across Europe and Australia, offering over 30 million customers across 9 brands a great form of entertainment in a safe, fair and sustainable environment. The company, which employs approximately 2,500 people, is listed on Nasdaq Stockholm Large Cap and is a member of the European Gaming and Betting Association (EGBA) and founding member of IBIA (International Betting Integrity Association). Kindred Group is audited and certified by eCOGRA for compliance with the 2014 EU Recommendation on Consumer Protection and Responsible Gambling (2014/478/EU). As of 11 October 2024, La Francaise des Jeux is the majority shareholder in Kindred Group plc. Read more on www.kindredgroup.com.

Nasdaq Stockholm, KIND-SDB

^[1] Based on 215,823,068 outstanding SDRs in Kindred, which excludes 14,303,068 treasury SDRs held by Kindred. Each SDR carries one vote.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/kindred-group/r/kindred-group-applies-for-delisting,c4055941

The following files are available for download:

https://mb.cision.com/Main/824/4055941/3074289.pdf

Project Odin – Application for delisting Final

View original content:https://www.prnewswire.co.uk/news-releases/kindred-group-applies-for-delisting-302286421.html

Fintech PR

DFC Expands Global Impact With Record-Breaking Investments in Fiscal Year 2024

Published

3 hours ago

October 24, 2024

CISION (PR Newswire)

Total annual commitments more than doubled since agency’s launch five years ago
Driving global development with more than 180 strategic transactions

WASHINGTON, Oct. 24, 2024 /PRNewswire/ — The U.S. International Development Finance Corporation today announced that it committed a record $12 billion in investments in Fiscal Year 2024 to projects that are improving lives and promoting economic growth across the developing world by expanding access to food, energy, healthcare, critical infrastructure, and financial services.

In Fiscal Year 2024, DFC tackled some of the world’s greatest challenges by supporting transactions in 44 countries, with a total portfolio spanning over 110 countries across Africa, the Middle East, Latin America, Europe, and the Indo-Pacific. DFC’s new commitments are expected to finance 450,000 smallholder farmers, generate 4,600GWh of renewable energy, improve healthcare for more than 11 million patients, and fuel growth for 380,000 micro, small, and medium-sized businesses.

“Fiscal Year 2024 was a remarkable year for DFC, both in terms of volume of investment and our impact on some of the world’s most pressing challenges. In just five years since its creation, DFC’s private-sector-led approach has established DFC as a pivotal instrument in U.S. foreign policy and a key player in the development finance space,” said DFC CEO Scott Nathan. “The new investments made this year will provide badly needed financing to entrepreneurs and businesses, driving economic growth and stability in the countries where we work. I’m proud of the hard work and accomplishments of the DFC team to support development and bolster U.S. national security.”

In Fiscal Year 2024, DFC committed to over 180 transactions. Activity included:

Invested where American values and interests intersect. DFC’s dual focus on global development and American national security helps ensure its investments benefit both the United States and the host countries.

In Angola, DFC’s board approved a loan of up to $553 million to the Lobito Atlantic Railway to support the upgrade and rehabilitation of more than 800 miles of rail and a mineral port to help ensure the reliable transport of minerals that are critical to the clean energy transition. In a related transaction, DFC also committed a $3.4 million technical assistance grant to Pensana to conduct feasibility studies to advance development of a rare earth mine and refining facility in the Lobito Corridor.
In Indonesia, an up to $126 million DFC loan to PT Medco Cahaya Geothermal will finance the development of approximately 31.4MW of geothermal power generation capacity in East Java.
In South Africa, a $50 million equity investment in TechMet will support the development of the Phalaborwa Rare Earths project, a rare earth element processing facility that will develop a more diverse, resilient, and sustainable critical mineral supply chain, drive the clean energy transition, and create economic opportunity for local communities.

Provided critical support to the people and businesses impacted by the war in Ukraine. DFC continued its support for Ukraine, committing more than $580 million to a wide range of sectors crucial to the country’s recovery and stability amid the conflict. This included one of its signature tools to address the most urgent Ukrainian economic needs and lay a foundation for long-term resilience: political risk insurance.

$10 million in political risk insurance will support the rebuilding of a water treatment and water filtration equipment manufacturing facility destroyed during Russia’s invasion.
$50 million in political risk insurance will support a reinsurance facility brokered by Aon and distributed by ARX to build a portfolio of war risk insurance policies for companies operating in Ukraine and to support ARX in expanding its war risk insurance offering in the country.
$150 million in political risk insurance will help maintain the country’s agriculture operations and alleviate food insecurity.

Strengthened global supply chains. DFC invested in infrastructure to bolster access to essential goods and services including food, energy, healthcare, technology, and critical minerals.

In South Africa, a €110 million DFC loan will help Aspen Pharmacare expand its capacity to deliver medicines, diabetes insulin, and pediatric vaccines, increasing local access to life-saving medicines and vaccines across Africa.
In Zambia, a $10 million loan to Seba Foods Zambia Ltd. will support the expansion of the company’s storage and production capacity and provide affordable, soy-based consumer food products, strengthening the food value chain in Zambia.
In Türkiye, a $350 million loan to Enerjisa Enerji Üretim A.Ş. will finance the development, construction, and operation of nine onshore wind power plants in Western Türkiye that are expected to generate approximately 2.51 terawatt-hours per year.

Advanced high-standard, transparent investing to achieve sustained impact. DFC adheres to the highest standards on worker rights and the environment and works to ensure its investments deliver a sustained positive impact.

In India, DFC committed a $10 million loan to Nepra Resource Management for construction of material recovery facilities for the recycling and sustainable disposal of material waste that will reduce waste in landfills.
Across Africa, a $250 million tier 2 capital loan to Africa Finance Corporation will strengthen the capital position of a key pan-African multilateral development finance institution to support its operating activities, including investment activities consisting of infrastructure projects critical to economic growth and development.
In the Western Hemisphere, a $50 million equity investment in PI Fund V (Ontario), L.P. will increase investments in Latin American infrastructure and address financing gaps to develop critical projects, with a primary focus on Brazil, Colombia, Peru, and Mexico.

Supported the world’s low-income countries and underserved communities. DFC focuses a majority of its transactions in low- and lower-middle-income countries and prioritizes investments that benefit women and other underserved populations.

In India, a $50 million loan to InCred Financial Services Ltd. will support lending to women and women-owned businesses using a technology-enabled lending approach designed to expand access to underserved entrepreneurs and individuals.
In the Dominican Republic, where nearly one quarter of the population lives below the poverty line, DFC committed $200 million in financing to Banco Popular Dominicano, S.A. to support lending to small businesses, with a focus on women entrepreneurs.
In the Philippines, DFC committed a $20 million loan to Lhoopa Singapore Pte. Ltd. that will support a digital platform focused on the development of affordable housing for low-income families throughout the country.

Learn more about DFC’s record-breaking year.

The U.S. International Development Finance Corporation (DFC) partners with the private sector to finance solutions to the most critical challenges facing the developing world today. We invest across sectors including energy, healthcare, infrastructure, agriculture, and small business and financial services. DFC investments adhere to high standards and respect the environment, human rights, and worker rights.

Logo – https://mma.prnewswire.com/media/2514418/DFC_Horizontal_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/dfc-expands-global-impact-with-record-breaking-investments-in-fiscal-year-2024-302286349.html